Antibodies to cyclic citrullinized peptide in rheumatoid arthritis
- Authors: Aleksandrova EN1, Chemeris NA1, Karateev DE1, Novikov AA1, Brodetskaya KA1, Nasonov EL1
-
Affiliations:
- Issue: Vol 79, No 12 (2004)
- Pages: 64-68
- Section: Editorial
- Submitted: 09.04.2020
- Published: 15.12.2004
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29967
- ID: 29967
Cite item
Full Text
Abstract
arthritis (RA).
Material and methods. The study was made of 85 RA patients. Of them, 48 patients had early RA,
i.e. of 8 month and less duration. The control group consisted of 35 patients with non-differentiated
arthritis (NBA) and 8 healthy donors. Concentrations of CCP antibodies, rheumatoid factor (RF)
IgM and RF IgA were measured with enzyme immunoassay (EIA).
Results. The level of CCP antibodies in RA patients (76.3 ± 43.8; median 100.0 U/ml) was significantly
higher than in NDA patients (25.1 ± 43.9; median 0.8 U/ml; p < 0.05) or in donors
(0.38 ± 0.36; median 0.2 U/ml; p < 0.05). A correlation was found between the CCP antibodies level
and that ofRF IgM (/ = 15.4; p = 0.001) and RF IgA (/ = 10.3; p = 0.001). Sensitivity (82%)
and specificity (90%) of CCP antibodies in RA diagnosis was higher than these parameters for RF
IgM and IgA (78%o, 86%> and 72%, 83%, respectively). Simultaneous tests for CCP antibodies, RF
IgM and RF IgA led to a 93% specificity. CCP antibodies were detected in 50% patients seronegative
by RF IgM and in 62% patients seronegative by IgA. Detection of CCP antibodies was closely associated
with early RA (x2 = 30.8;p = 0.0001).
Conclusion. The EI A for CCP antibodies is a sensitive and specific serological test for early RA diagnosis.
About the authors
E N Aleksandrova
N A Chemeris
D E Karateev
A A Novikov
K A Brodetskaya
E L Nasonov
References
- Насонова В. А., Насонов Е. Л. Рациональная фармакотерапия ревматических заболеваний. М.: Литтера; 2003.
- Arnett F. С., Edworth S. M., Bloch D. A. et al. American Rheumatism Assosiation 1987 revised criteria for the classification of rheumatoid arthritis. Arthr. and Rheum. 1988; 31: 315- 324.
- Shmerting R. H., Delbanco T. L. The rheumatoid factor an analysis of clinical utility. Am. J. Med. 1991; 91: 528-534.
- Nienhius R. L. F., Maudema E. A. A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann. Rheum. Dis. 1964; 23: 302-305.
- Насонов Е. Л., Штутман В. З., Сперанский А. И. Антиперинуклеарный фактор и антитела к кератину: новые серологические маркеры ревматоидного артрита. Клин, ревматол. 1993; 2: 20-24.
- Young В. J., Mallya R. K., Leslia R. D. Ami keratin antibodies in rheumatoid arthritis. Br. Med. J. 1979: 2: 97-99.
- Simon M., Girbal E., Sebbag M. et al. The cytokeratin filament-aggregating protein fllaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 1993; 92: 1387-1393.
- Sebbag M., Simon M., Vincent С. et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 1995; 95: 2672-2679.
- Schellekens G. A., de Jong B. A., van den Hoogen F. H. et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 1998; 101: 273-281.
- Schellekens G. A., Visser H., de Jong B. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthr. and Rheum. 2000; 43: 155- 163.
- Kroot E. J., de Jong B. A., van Leeuwen M. A. et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthr. and Rheum. 2000; 43: 1831-1835.
- van Jaarsveld C. H., ter Borg E. J., Jacobs J. W. et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin. Exp. Rheumatol. 1999; 17: 689-697.
- Bizzaro N., Mazzanti G., Tonutti E. et al. Diagnostic accuracy of the anti-citruliine antibody assay for rheumatoid arthritis. Clin. Chem. 2001; 47: 1089-1093.
- van Boekel M. A., Vossenaar E. R., van den Hoogen F. H. et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthr. Res. Ther. 2002; 4: 87-93.
- Combe В., Dougados M., Goupille P. et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthr. and Rheum. 2001; 44: 1736-1743.
- van der Heijde D. M., van't Hof M. A., van Riel P. L. et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann. Rheum. Dis 1992; 51: 177-181.
- Чичасова Н. В., Насонова М. Б., Степанец О. В., Насонов Е. Л. Современные подходы к оценке активности ревматоидного артрита. Тер. арх. 2002; 5: 57-60.
- Highton J., Hessian P. A solid-phase enzyme immunoassay for C-reactive protein: clinical value and the effect of rheumatoid factor. J. Immunol. Meth. 1984; 68: 185-192.
- Vamvakas E. С. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a rewiew of the concepts and methods. Arch. Pathol. Lab. Med. 1998; 122: 675-686.
- Goldbach-Mansky R., Lee J., McCoy A. et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. Ther. 2000; 2: 236-243.
- Bas S., Pemeger Т., Seitz M. et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002; 41: 809-814.
- Jansen A., van der Horst-Bruisma I. et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J. Rheumatol. 2002; 29: 2074-2076.
- Bas S., Genevay S., Meyer O. et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003; 42: 677-680.
- Xiaofegng Zeng, Maixing Ai, Xiping Tian et al. Diagnostic value of anti-cyclice citrullinated peptide antibody in patients with rheumatoid arthritis. J. Rheumatol. 2003; 30: 1451 - 1455.
- Lee D., Schur P. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann. Rheum. Dis. 2003; 62: 870-874.
- Dubucquoi S., Solau-Gervais E., Lefranc D. et al. Evaluation as hallmarks for the diagnosis of rheumatic diseases. Ann. Rheum. Dis. 2004; 63: 415-419.
- Saraux A., Berthelot J. M., Devauchelle V. et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J. Rheumatol. 2003; 30: 2535-2539.
- Suzuki K., Sawada Т., Matsui T. et al. High diagnostic performance of EL1SA detection antibodies to citrullinated antigens in rheumatoid arthritis. Scand. J. Rheumatol. 2003; 32: 197-204.
- Bombardieri M., Alessandri C., Labbardia G. et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis С infection-associated polyarticular involvement. Arthr. Res. Ther. 2004; 6: R137-R141
Supplementary files
![](/img/style/loading.gif)